The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting
- PMID: 36657483
- PMCID: PMC10189896
- DOI: 10.1080/14728222.2022.2170779
The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting
Abstract
Introduction: In contrast to other breast cancer subtypes, there are currently limited options of targeted therapies for triple-negative breast cancer (TNBC). Immense research has demonstrated that not only cancer cells but also stromal cells and immune cells in the tumor microenvironment (TME) play significant roles in the progression of TNBC. It is thus critical to understand the components of the TME of TNBC and the interactions between the various cell populations.
Areas covered: The components of the TME of TNBC identified by single-cell technologies are reviewed. Furthermore, the molecular interactions between the cells and the potential therapeutic targets contributing to the progression of TNBC are discussed.
Expert opinion: Single-cell omics studies have contributed to the classification of cells in the TME and the identification of important cell types involved in the progression and the treatment of the tumor. The interactions between cancer cells and stromal cells/immune cells in the TME have led to the discovery of potential therapeutic targets. Experimental data with spatial and temporal resolution will further boost the understanding of the TME of TNBC.
Keywords: immunotherapy; single-cell analysis; triple-negative breast cancer; tumor microenvironment.
Conflict of interest statement
Declaration of interests
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Figures


Similar articles
-
Targeting tumor-stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model.Breast Cancer Res. 2024 Jan 5;26(1):5. doi: 10.1186/s13058-023-01760-y. Breast Cancer Res. 2024. PMID: 38183074 Free PMC article.
-
Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.Expert Opin Ther Targets. 2022 May;26(5):405-425. doi: 10.1080/14728222.2022.2077188. Epub 2022 May 23. Expert Opin Ther Targets. 2022. PMID: 35574694 Free PMC article. Review.
-
Tumor microenvironment and immunotherapy for triple-negative breast cancer.Biomark Res. 2024 Dec 31;12(1):166. doi: 10.1186/s40364-024-00714-6. Biomark Res. 2024. PMID: 39741315 Free PMC article. Review.
-
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.Pharmacol Res. 2020 Mar;153:104683. doi: 10.1016/j.phrs.2020.104683. Epub 2020 Feb 9. Pharmacol Res. 2020. PMID: 32050092 Review.
-
Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer.Int Immunopharmacol. 2023 Jun;119:110250. doi: 10.1016/j.intimp.2023.110250. Epub 2023 May 8. Int Immunopharmacol. 2023. PMID: 37163922 Review.
Cited by
-
Spatial profiling reveals unique immune microenvironment in premenopausal triple-negative breast cancer associated with therapy response.J Transl Med. 2025 Jul 10;23(1):761. doi: 10.1186/s12967-025-06786-8. J Transl Med. 2025. PMID: 40640880 Free PMC article.
-
Targeting tumor-stromal interactions in triple-negative breast cancer using a human vascularized micro-tumor model.Breast Cancer Res. 2024 Jan 5;26(1):5. doi: 10.1186/s13058-023-01760-y. Breast Cancer Res. 2024. PMID: 38183074 Free PMC article.
-
Predictive value of tumoral and peritumoral radiomic features in neoadjuvant chemotherapy response for breast cancer: a retrospective study.Radiol Med. 2025 May;130(5):598-612. doi: 10.1007/s11547-025-01969-1. Epub 2025 Feb 24. Radiol Med. 2025. PMID: 39992329
-
Remodeling of tumour microenvironment: strategies to overcome therapeutic resistance and innovate immunoengineering in triple-negative breast cancer.Front Immunol. 2024 Dec 10;15:1455211. doi: 10.3389/fimmu.2024.1455211. eCollection 2024. Front Immunol. 2024. PMID: 39720730 Free PMC article. Review.
-
Spatial Architecture of Single-Cell and Vasculature in Tumor Microenvironment Predicts Clinical Outcomes in Triple-Negative Breast Cancer.Mod Pathol. 2025 Feb;38(2):100652. doi: 10.1016/j.modpat.2024.100652. Epub 2024 Nov 8. Mod Pathol. 2025. PMID: 39522644
References
-
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7–33 - PubMed
-
- American Cancer Society. Triple-negative Breast Cancer [Internet]. 2022; Available from: https://www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer...
-
- Perou CM. Molecular Stratification of Triple-Negative Breast Cancers. Oncologist. 2010;15:39–48 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources